Use of proton pump inhibitors in hematopoietic stem cell transplantation does not increase the frequency of febrile neutropenia

M.C. Ozkan, A. Donmez, A. Arslan, S. Aydemir, M. Tombuloglu

Department of Hematology, Internal Medicine, and Microbiology; Ege University Medical School, Izmir, Turkey. zjdocchina@163.com

---

• Hematology

OBJECTIVE: Despite the fact that proton pump inhibitor (PPI) use is a risk factor for infections in heterogeneous groups of patients, there are only a limited data related to PPI use and febrile neutropenic episodes (FNEs) in hematopoietic stem cell transplantation (HSCT) patients.

PATIENTS AND METHODS: In a 7-year period, we retrospectively reviewed 145 HSCT data to identify a risk factor for PPI use for febrile neutropenia. The follow-up process of 125 (86.2%) of the HSCTs was complicated with FNEs.

RESULTS: A multivariate analysis indicated that PPI use was not significantly associated with FNEs (Odds ratio [OR]: 0.46; 95% Confidence Interval [CI] 0.12-2.16; p = 0.24) or bacterial culture positivity (OR: 1.37; 95% CI 0.45-4.18; p = 0.58).

CONCLUSIONS: Our study revealed that PPI use does not appear to be a risk factor for FNE or bacterial culture positivity for HSCT patients but further studies are needed.

Free PDF Download